Boston Partners
IONS icon

Boston Partners’s Ionis Pharmaceuticals IONS Stock Holding History

Boston Partners’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-8,037
Closed -$298K – 725
2022
Q1 		$298K Buy
8,037
+247
+3% +$8.09K ﹤0.01% 655
2021
Q4 		$237K Buy
+7,790
New +$245K ﹤0.01% 662

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
TBC
Tweedy, Browne Co Stamford, Connecticut $1.26B AUM 33.88% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return

Boston Partners's IONS Position: Q2 2022 in Review

Boston Partners sold out of Ionis Pharmaceuticals (IONS) in Q2 2022, closing a stake of 8,037 shares — an estimated $298K sold.

Boston Partners first reported a position in IONS in Q4 2021 and held it in 2 quarters. The position peaked at $298K in Q1 2022. 349 funds tracked by Wall St. Rank hold IONS as of Q2 2022.

  • Boston Partners reported no remaining Ionis Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Boston Partners sold 8,037 Ionis Pharmaceuticals shares in Q2 2022, an estimated $298K.
  • Boston Partners first reported a position in Ionis Pharmaceuticals in Q4 2021 and held it in 2 quarters.
  • Boston Partners's Ionis Pharmaceuticals position peaked at $298K in Q1 2022.
  • 349 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q2 2022.

Based on Boston Partners's 13F filing for Q2 2022, filed 10 Aug 2022.